Σellas executes Clinical Trials on behalf of pharmaceutical and research centres and is also involved in the development of its own drugs from Phase I-III.
Σellas clinical investigational team backed by study nurses and project managers is proud of accomplishing successfully a number of clinical studies in the therapy areas of: infectious diseases, haematology, osteoporosis, multiple sclerosis and cardiovascular diseases.
Clinical Trials, as part of medical research, are the most important endeavours in order to assess the efficacy of a new, or established, drug, device, or treatment protocol and its safety. There are stringent requirements involved in initiating and conducting Clinical Trials as the patient’s well-being is our top priority. These Trials can only take place once satisfactory information has been gathered on the quality of the product and its non-clinical safety and, depending on the Phase of the trial, clinical safety and efficacy data as well. Depending on the type of product and the stage of its development, investigators enrol healthy volunteers and/or patients into small pilot studies initially, followed by larger scale studies in patients that often compare the new product with the currently prescribed treatment.
Clinical Trials are only a small part of the research that goes into developing a new treatment. Potential drugs, for example, first have to be discovered, purified, characterized, and tested in labs (in cell and animal studies) before ever undergoing clinical trials. In all, about 1,000 potential drugs are tested before just one reaches the point of being tested in a Clinical Trials. For example, a new cancer drug has, on average, at least 6 years of research behind it before it even makes it to Clinical Trials. But the major holdup in making new cancer drugs available is the time it takes to complete Clinical Trials themselves. On average, about 8 years pass from the time a cancer drug enters Clinical Trials until it receives approval from regulatory agencies for sale to the public. Drugs for other diseases have similar timelines.
Due to the in-house expertise of our highly experienced management group in addition to our physicians, scientists, study nurses and regulatory affairs specialists we are able to serve both, as a dedicated clinical research centre supporting pharmaceutical and device companies with patient enrolment and therapeutic procedures under ICH-GCP guidelines and optimal study data collection in addition to developing, or co-developing, our own drugs across various indications.